ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Personal Finance
  • Markets
    • Stocks
    • Global Markets
    • IPO
    • Companies
    • Currency
    • Commodities
  • My Money
  • Web Stories
  • Calculators
    • Income Tax Calculator
    • Home Loan/EMI Calculator
    • Mutual Fund Returns Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • SIP calculator
    • Lumpsum Calculator
    • SWP Calculator
  • Videos
    • M Se Market
    • Jeb Zindagi Zaroorat
    • Light Camera Stocks
    • Tech Takes
    • Big Bulls Ka Nishana
    • Paisa Wasool
    • Commodity Ke MrityunjayMantra
    • The Right Property Show
  • Economy & Infra
    • Policy & Initiatives
    • Agriculture
    • Telecom
    • Aviation
    • Railways
    • Retail
    • Roadways
    • World Economy
  • Exclusive
    • Wealth Guide
    • Interviews
  • Auto
    • Cars
    • Bikes
    • Electric Vehicle
    • Commercial Vehicles
  • Tech
    • Mobiles
    • Gadgets
    • Reviews
    • Tips and Tricks
    • Apps
  • Samco Acers
  • Samco Mission Ace The Index
  • Real Estate
    • Home Buyers
    • Builders
  • Trending
    • Entertainment
    • Politics
    • Lifestyle
    • Travel
    • Sports
    • Viral
    • Education
    • Jobs
Read in App
Business News » Companies News

US drugmaker Pfizer abandons plan to split into two companies; stock falls nearly 2%

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
US drugmaker Pfizer abandons plan to split into two companies; stock falls nearly 2%
Pfizer world headquarters in New York, United States. Image Source: Reuters

US drugmaker Pfizer Inc, which has been considering a split into two companies for more than two years, said on Monday it would not do so because the move would not create any shareholder value.

Pfizer said a split would not boost cash flow or better position the businesses competitively. It would also disrupt operations, have inherent costs and fail to deliver any tax efficiencies, the company said.

Pfizer will keep its low-growth generics and patent-protected branded medicines separate, giving it the option to split later if "factors materially change at some point in the future."

Pfizer said the decision would not affect its 2016 financial forecast. Its shares fell 1.5% to $33.75 in morning trading, amid a 1% decline in the ARCA Pharmaceutical Index of large drugmakers.

The move follows the collapse of Pfizer's planned $160 billion (nearly Rs 10.64 lakh crore) acquisition of Irish drugmaker Allergan Inc after a change in US law negated the tax benefits for companies moving corporate headquarters to overseas locales through acquisitions.

Investors were expecting the company to step back from the split, Sanford Bernstein analyst Tim Anderson said in a research note. 

"The company seems likely to leave open its option for a future split-up, but more immediately it may continue hunting for megers and acquisitions (M&A) targets," Anderson wrote.

Pfizer began openly planning for a possible split in early 2014, saying it would operate the businesses as separate divisions and track their progress for three years before reaching a decision. In August, it said it would decide by year-end.

Pfizer said the sum-of-the-parts analysis showed no benefit to shareholders, and that tax costs and business disruptions were factors it considered.

The company had considered the move largely because its patent-protected medicines routinely enjoyed sales growth while demand for its generics usually declined.

But the $15 billion (nearly Rs 99,791.25 crore) purchase of Hospira a year ago has bolstered Pfizer's wide array of generics, which the company calls "essential products." Hospira makes generic injectable hospital products and biosimilars, which are cheaper versions of the world's leading biotech drugs.

Annual sales of Pfizer's generic portfolio should grow by a single-digit percentage rate in coming years, JPMorgan analyst Chris Schott said in a research note. He forecast a 3% rise in the company's overall annual sales through 2020, resulting in 8% earnings growth.

Investors shifted their focus to whether Pfizer would split after the company terminated the Allergan deal in April.

In August, Pfizer said it was buying Medivation Inc for $14 billion (nearly Rs 93,138.5 crore) to get access to blockbuster prostate cancer drug Xtandi for its growing oncology roster.

That deal illustrates a shift in Pfizer's mergers and acquisitions strategy from lowering taxes, which was the rationale behind the failed Allergan bid, to strengthening its lineup of branded drugs, especially lucrative cancer treatments. 

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
PfizerPharmaPfizer IncAllerganacquisitionM&AMedivationUS
Written By: Reuters
Updated: Mon, Sep 26, 2016
10:48 pm
Reuters
RELATED NEWS
Pfizer completes sale of 4 products deal to Piramal Enterprises Pfizer completes sale of 4 products deal to Piramal Enterprises
Pfizer to buy Medivation for $14 billion Pfizer to buy Medivation for $14 billion
Pfizer plans to bring more global drugs to India Pfizer plans to bring more global drugs to India
Pfizer expected to bid for acquisition of US cancer drug company Medivation Pfizer expected to bid for acquisition of US cancer drug company Medivation

LATEST NEWS

Explained: Why gold financiers often offer more top-up on existing loan

Income Tax Return Filing deadline: 10 lesser-known tax exemptions you can claim while filing ITR

Tom Holland says he's taking 'a year off' acting after working on 'The Crowded Room'

Decoding IRCTC’s revolutionary 35 paise travel insurance scheme

EXCLUSIVE | Nifty at 40,000? Raamdeo Agrawal says not the right time to stay away from market

RBI MPC retains repo rate at 6.5%, projects 6.5% GDP & 5.1% inflation for FY24

50% of Rs 2,000 notes back in banking system, says RBI Governor Shaktikanta Das

HDFC Bank suspends employee for abusing colleagues during online meeting after video goes viral

Cyclone Biparjoy: From location to severity, all you need to know

USAID Administrator Samantha Power meets World Bank President Ajay Banga; discusses climate finance, financial support to Ukraine

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
© 2023. Indiadotcom Digital Private Limited. All Rights Reserved.
LIVE TV